Type2 diabetes is largely preventable by staying at a normal weight, exercising regularly, and eating a healthy diet (high in fruits and vegetables and low in sugar and saturated fats).[1]
Treatment involves exercise and dietary changes.[1] If blood sugar levels are not adequately lowered, the medication metformin is typically recommended.[7][14] Many people may eventually also require insulin injections.[9] In those on insulin, routinely checking blood sugar levels (such as through a continuous glucose monitor) is advised; however, this may not be needed in those who are not on insulin therapy.[15]Bariatric surgery often improves diabetes in those who are obese.[8][16]
Rates of type2 diabetes have increased markedly since 1960 in parallel with obesity.[17] As of 2015, there were approximately 392million people diagnosed with the disease compared to around 30million in 1985.[11][18] Typically, it begins in middle or older age,[6] although rates of type 2 diabetes are increasing in young people.[19][20] Type 2 diabetes is associated with a ten-year-shorter life expectancy.[10] Diabetes was one of the first diseases ever described, dating back to an Egyptian manuscript from c.1500BCE.[21] The importance of insulin in the disease was determined in the 1920s.[22]
Type 2 diabetes is typically a chronic disease associated with a ten-year-shorter life expectancy.[10][25] This is partly due to a number of complications with which it is associated, including: two to four times the risk of cardiovascular disease, including ischemic heart disease and stroke; a 20-fold increase in lower limb amputations, and increased rates of hospitalizations.[10] In the developed world, and increasingly elsewhere, type2 diabetes is the largest cause of nontraumatic blindness and kidney failure.[26] It has also been associated with an increased risk of cognitive dysfunction and dementia through disease processes such as Alzheimer's disease and vascular dementia.[27] Other complications include hyperpigmentation of skin (acanthosis nigricans), sexual dysfunction, diabetic ketoacidosis, and frequent infections.[23][28][29] There is also an association between type 2 diabetes and mild hearing loss.[30]
Causes
The development of type2 diabetes is caused by a combination of lifestyle and genetic factors.[26][31] While some of these factors are under personal control, such as diet and obesity, other factors are not, such as increasing age, female sex, and genetics.[10] Generous consumption of alcohol is also a risk factor.[32] Obesity is more common in women than men in many parts of Africa.[33] The nutritional status of a mother during fetal development may also play a role, with one proposed mechanism being that of DNA methylation.[34] The intestinal bacteria Prevotella copri and Bacteroides vulgatus have been connected with type2 diabetes.[35]
Lifestyle factors are important to the development of type2 diabetes, including obesity and being overweight (defined by a body mass index of greater than 25), lack of physical activity, poor diet, psychological stress, and urbanization.[10][36] Excess body fat is associated with 30% of cases in those of Chinese and Japanese descent, 60–80% of cases in those of European and African descent, and 100% of cases in Pima Indians and Pacific Islanders.[13] Among those who are not obese, a high waist–hip ratio is often present.[13] Smoking appears to increase the risk of type2 diabetes.[37] A lack of sleep has also been linked to type2 diabetes.[38] Laboratory studies have linked short-term sleep deprivations to changes in glucose metabolism, nervous system activity, or hormonal factors that may lead to diabetes.[38]
Dietary factors also influence the risk of developing type2 diabetes. Consumption of sugar-sweetened drinks in excess is associated with an increased risk.[39][40] The type of fats in the diet are important, with saturated fats and trans fatty acids increasing the risk, and polyunsaturated and monounsaturated fat decreasing the risk.[31] Eating a lot of white rice appears to play a role in increasing risk.[41] A lack of exercise is believed to cause 7% of cases.[42]Persistent organic pollutants may also play a role.[43]
Most cases of diabetes involve many genes, with each being a small contributor to an increased probability of becoming a type2 diabetic.[10] The proportion of diabetes that is inherited is estimated at 72%.[44] More than 36genes and 80single nucleotide polymorphisms (SNPs) had been found that contribute to the risk of type2 diabetes.[45][46] All of these genes together still only account for 10% of the total heritable component of the disease.[45] The TCF7L2allele, for example, increases the risk of developing diabetes by 1.5times and is the greatest risk of the common genetic variants.[13] Most of the genes linked to diabetes are involved in pancreatic beta cell functions.[13]
Type2 diabetes is due to insufficient insulin production from beta cells in the setting of insulin resistance.[13] Insulin resistance, which is the inability of cells to respond adequately to normal levels of insulin, occurs primarily within the muscles, liver, and fat tissue.[59] In the liver, insulin normally suppresses glucose release. However, in the setting of insulin resistance, the liver inappropriately releases glucose into the blood.[10] The proportion of insulin resistance versus beta cell dysfunction differs among individuals, with some having primarily insulin resistance and only a minor defect in insulin secretion and others with slight insulin resistance and primarily a lack of insulin secretion.[13]
Other potentially important mechanisms associated with type2 diabetes and insulin resistance include: increased breakdown of lipids within fat cells, resistance to and lack of incretin, high glucagon levels in the blood, increased retention of salt and water by the kidneys, and inappropriate regulation of metabolism by the central nervous system.[10] However, not all people with insulin resistance develop diabetes since an impairment of insulin secretion by pancreatic beta cells is also required.[13]
In the early stages of insulin resistance, the mass of beta cells expands, increasing the output of insulin to compensate for the insulin insensitivity, so that the disposition index remains constant.[60] But when type 2 diabetes has become manifest, a type 2 diabetic will have lost about half of their beta cells.[60]Fatty acids in the beta cells activate FOXO1, resulting in apoptosis of the beta cells.[60] The disposition index drops and diabetes becomes manifest.
The causes of the aging-related insulin resistance seen in obesity and in type2 diabetes are uncertain. Effects of intracellular lipid metabolism and ATP production in liver and muscle cells may contribute to insulin resistance.[61] New evidence also points to a role of a brain region called the hypothalamus in the development of insulin resistance. A gene called Dusp8 is linked with an increased risk for diabetes.[62] This gene codes for a protein that regulates neuronal signaling in the hypothalamus. Also, infusions into the hypothalamus of a hormone called leptin normalize blood glucose and diminish insulin resistance in diabetic animals.[63] Activation of hypothalamic cells by leptin has an important role in maintaining normal levels of blood glucose. Thus, both the endocrine cells of the pancreas AND cells in the hypothalamus may have a role in the etiology of type 2 diabetes.
Hypothalamic cells regulate blood glucose via projections to the autonomic nervous system. Autonomic innervation of liver and muscle cells stimulates an increased uptake of glucose. In diabetic humans, the control of blood glucose by the autonomic nervous system is abnormal.[64] Leptin-sensitive, glucose regulating neurons become resistant to leptin during aging or during exposure to a high-fat diet. These leptin-resistant neurons fail to restrain food intake, obesity, and blood glucose. The reasons for this lowered responsiveness to leptin are uncertain and are part of the puzzle of the causes of type2 diabetes.[65]
Blood glucose levels can also be normalized in diabetic rodents by a single intrahypothalamic infusion of Fibroblast Growth Factor 1 (FGF1), an effect that persists for months even in severely diabetic animals. This remarkable cure of diabetes is accomplished by a stimulation of accessory brain cells called astrocytes.[66][67] Hypothalamic astrocytes that produce Fatty Acid Binding Protein 7 (FABP7) are targets of FGF1; these cells are also in close contact with leptin-sensitive neurons, influence their function, and regulate leptin sensitivity.[68][69] An abnormal function of FABP7+ astrocytes thus may contribute to the resistance to leptin and insulin that appear during aging and during exposure to high-fat diets.
During aging, FABP7+ astrocytes develop cytoplasmic granules derived from degenerating mitochondria. This mitochondrial degeneration is partly due to the oxidative stress of the heightened amounts of fatty acids that are taken up by these cells and oxidized within mitochondria.[70][71] A pathological degeneration of mitochondria in these cells may compromise their normal functions and contribute to abnormalities in the control of blood glucose by the hypothalamus.
The World Health Organization definition of diabetes (both type1 and type2) is for a single raised glucose reading with symptoms, otherwise raised values on two occasions, of either:[74]
fasting plasma glucose ≥ 7.0mmol/L (126mg/dL)
or
with a glucose tolerance test, two hours after the oral dose a plasma glucose ≥ 11.1mmol/L (200mg/dL)
A random blood sugar of greater than 11.1mmol/L (200mg/dL) in association with typical symptoms[23] or a glycated hemoglobin (HbA1c) of ≥48mmol/mol (≥6.5 DCCT%) is another method of diagnosing diabetes.[10] In 2009 an International Expert Committee that included representatives of the American Diabetes Association (ADA), the International Diabetes Federation (IDF), and the European Association for the Study of Diabetes (EASD) recommended that a threshold of ≥48mmol/mol (≥6.5 DCCT%) should be used to diagnose diabetes.[75] This recommendation was adopted by the American Diabetes Association in 2010.[76] Positive tests should be repeated unless the person presents with typical symptoms and blood sugars >11.1mmol/L (>200mg/dL).[75]
Threshold for diagnosis of diabetes is based on the relationship between results of glucose tolerance tests, fasting glucose or HbA1c and complications such as retinal problems.[10] A fasting or random blood sugar is preferred over the glucose tolerance test, as they are more convenient for people.[10] HbA1c has the advantages that fasting is not required and results are more stable but has the disadvantage that the test is more costly than measurement of blood glucose.[78] It is estimated that 20% of people with diabetes in the United States do not realize that they have the disease.[10]
Type2 diabetes is characterized by high blood glucose in the context of insulin resistance and relative insulin deficiency.[79] This is in contrast to type 1 diabetes in which there is an absolute insulin deficiency due to destruction of islet cells in the pancreas and gestational diabetes that is a new onset of high blood sugars associated with pregnancy.[13] Type1 and type2 diabetes can typically be distinguished based on the presenting circumstances.[75] If the diagnosis is in doubt antibody testing may be useful to confirm type1 diabetes and C-peptide levels may be useful to confirm type2 diabetes,[80] with C-peptide levels normal or high in type2 diabetes, but low in type1 diabetes.[81]
Screening
Universal screening for diabetes in people without risk factors or symptoms is not recommended.[82][83] Screening is recommended by the World Health Organization, the United States Preventive Services Task Force (USPSTF), and the American Diabetes Association for high-risk adults.[84][85][86] Risk factors considered by the USPSTF include adults over 35 years old who are overweight or have obesity and adults without symptoms whose blood pressure is greater than 135/80mmHg.[87][needs update][84] For those whose blood pressure is less, the evidence is insufficient to recommend for or against screening.[87][needs update] The American Diabetes Society recommends screening for adults with a body mass index (BMI) over 25.[86] For people of Asian descent, screening is recommended if they have a BMI over 23.[86] Other high risk groups include people with a first degree relative with diabetes; some ethnic groups, including Hispanics, African-Americans, and Native-Americans; a history of gestational diabetes; polycystic ovary syndrome; excess weight; and conditions associated with metabolic syndrome.[23] There is no evidence that screening changes the risk of death and any benefit of screening on adverse effects, incidence of type 2 diabetes, HbA1c or socioeconomic effects are not clear.[83][88]
In the UK, NICE guidelines suggest taking action to prevent diabetes for people with a body mass index (BMI) of 30 or more.[89] For people of Black African, African-Caribbean, South Asian and Chinese descent the recommendation to start prevention starts at the BMI of 27,5.[89] A study based on a large sample of people in England suggest even lower BMIs for certain ethnic groups for the start of prevention, for example 24 in South Asian and 21 in Bangladeshi populations.[90][91]
Onset of type2 diabetes can be delayed or prevented through proper nutrition and regular exercise.[92][93] Intensive lifestyle measures may reduce the risk by over half.[26][94] The benefit of exercise occurs regardless of the person's initial weight or subsequent weight loss.[95] High levels of physical activity reduce the risk of diabetes by about 28%.[96] Evidence for the benefit of dietary changes alone, however, is limited,[97] with some evidence for a diet high in green leafy vegetables[98] and some for limiting the intake of sugary drinks.[99] There is an association between higher intake of sugar-sweetened fruit juice and diabetes, but no evidence of an association with 100% fruit juice.[100] A 2019 review found evidence of benefit from dietary fiber.[101]
In those with impaired glucose tolerance, a 2019 systematic review found moderate-quality evidence that metformin, when compared to diet and exercise or a placebo intervention, appeared to delay or reduce the risk of developing type 2 diabetes.[102] This same review found moderate-quality evidence that when compared to intensive diet and exercise, Metformin did not reduce risk of developing type 2 diabetes, as well as very low-quality evidence that combining metformin with intensive diet and exercise does not appear to have any effect on risk of developing type 2 diabetes when compared to intensive diet and exercise alone.[102] This systematic review only found one suitable trial comparing metformin with sulphonylurea in reducing risk of type 2 diabetes but it did not report any patient-relevant outcomes.[102]
A 2017 review found that, long term, lifestyle changes decreased the risk by 28%, while medication does not reduce risk after withdrawal.[104] While low vitamin D levels are associated with an increased risk of diabetes, correcting the levels by supplementing vitamin D3 does not improve that risk.[105]
Management of type2 diabetes focuses on lifestyle interventions, lowering other cardiovascular risk factors, and maintaining blood glucose levels in the normal range.[26] Self-monitoring of blood glucose for people with newly diagnosed type2 diabetes may be used in combination with education,[106] although the benefit of self-monitoring in those not using multi-dose insulin is questionable.[26] In those who do not want to measure blood levels, measuring urine levels may be done.[107] Managing other cardiovascular risk factors, such as hypertension, high cholesterol, and microalbuminuria, improves a person's life expectancy.[26] Decreasing the systolic blood pressure to less than 140mmHg is associated with a lower risk of death and better outcomes.[108] Intensive blood pressure management (less than 130/80mmHg) as opposed to standard blood pressure management (less than 140-160 mmHg systolic to 85–100 mmHg diastolic) results in a slight decrease in stroke risk but no effect on overall risk of death.[109]
Intensive blood sugar lowering (HbA1c<6%) as opposed to standard blood sugar lowering (HbA1c of 7–7.9%) does not appear to change mortality.[110][111] The goal of treatment is typically an HbA1c of 7 to 8% or a fasting glucose of less than 7.2mmol/L (130mg/dL); however these goals may be changed after professional clinical consultation, taking into account particular risks of hypoglycemia and life expectancy.[86][112][113] Hypoglycemia is associated with adverse outcomes in older people with type 2 diabetes.[114] Despite guidelines recommending that intensive blood sugar control be based on balancing immediate harms with long-term benefits, many people– for example people with a life expectancy of less than nine years who will not benefit, are over-treated.[115]
It is recommended that all people with type2 diabetes get regular eye examinations.[13] There is moderate evidence suggesting that treating gum disease by scaling and root planing results in an improvement in blood sugar levels for people with diabetes.[116]
Lifestyle
Exercise
A proper diet and regular exercise are foundations of diabetic care,[23] with one review indicating that a greater amount of exercise improved outcomes.[117] Regular exercise may improve blood sugar control, decrease body fat content, and decrease blood lipid levels.[118]
Calorie restriction to promote weight loss is generally recommended.[119][77] Around 80 percent of obese people with type 2 diabetes achieve complete remission with no need for medication if they sustain a weight loss of at least 15 kilograms (33lb),[120][121] but most patients are not able to achieve or sustain significant weight loss.[122] Even modest weight loss can produce significant improvements in glycemic control and reduce the need for medication.[123]
Culturally appropriate education may help people with type2 diabetes control their blood sugar levels for up to 24 months.[131] There is not enough evidence to determine if lifestyle interventions affect mortality in those who already have type 2 diabetes.[94]
Stress management
Although psychological stress is recognized as a risk factor for type 2 diabetes,[10] the effect of stress management interventions on disease progression are not established.[132] A Cochrane review is under way to assess the effects of mindfulness‐based interventions for adults with type 2 diabetes.[133]
A second oral agent of another class or insulin may be added if metformin is not sufficient after three months.[112] Other classes of medications include: sulfonylureas, thiazolidinediones, dipeptidyl peptidase-4 inhibitors, SGLT2 inhibitors, and GLP-1 receptor agonists.[112] A 2018 review found that SGLT2 inhibitors and GLP-1 agonists, but not DPP-4 inhibitors, were associated with lower mortality than placebo or no treatment.[140]Rosiglitazone, a thiazolidinedione, has not been found to improve long-term outcomes even though it improves blood sugar levels.[141] Additionally it is associated with increased rates of heart disease and death.[142]
Injections of insulin may either be added to oral medication or used alone.[26] Most people do not initially need insulin.[13] When it is used, a long-acting formulation is typically added at night, with oral medications being continued.[23][26] Doses are then increased to effect (blood sugar levels being well controlled).[26] When nightly insulin is insufficient, twice daily insulin may achieve better control.[23] The long acting insulins glargine and detemir are equally safe and effective,[143] and do not appear much better than neutral protamine Hagedorn (NPH) insulin, but as they are significantly more expensive, they are not cost effective as of 2010.[144] In those who are pregnant, insulin is generally the treatment of choice.[23]
Blood pressure lowering
Many international guidelines recommend blood pressure treatment targets that are lower than 140/90mmHg for people with diabetes.[145] However, there is only limited evidence regarding what the lower targets should be. A 2016 systematic review found potential harm to treating to targets lower than 140 mmHg,[146] and a subsequent review in 2019 found no evidence of additional benefit from blood pressure lowering to between 130–140mmHg, although there was an increased risk of adverse events.[147]
2015 American Diabetes Association recommendations are that people with diabetes and albuminuria should receive an inhibitor of the renin-angiotensin system to reduce the risks of progression to end-stage renal disease, cardiovascular events, and death.[77] There is some evidence that angiotensin converting enzyme inhibitors (ACEIs) are superior to other inhibitors of the renin-angiotensin system such as angiotensin receptor blockers (ARBs),[148] or aliskiren in preventing cardiovascular disease.[149] Although a more recent review found similar effects of ACEIs and ARBs on major cardiovascular and renal outcomes.[150] There is no evidence that combining ACEIs and ARBs provides additional benefits.[150]
Other
The use of aspirin to prevent cardiovascular disease in diabetes is controversial.[77] Aspirin is recommended in people at high risk of cardiovascular disease, however routine use of aspirin has not been found to improve outcomes in uncomplicated diabetes.[151] 2015 American Diabetes Association recommendations for aspirin use (based on expert consensus or clinical experience) are that low-dose aspirin use is reasonable in adults with diabetes who are at intermediate risk of cardiovascular disease (10-year cardiovascular disease risk, 5–10%).[77]
Vitamin D supplementation to people with type 2 diabetes may improve markers of insulin resistance and HbA1c.[152]
Sharing their electronic health records with people who have type 2 diabetes helps them to reduce their blood sugar levels. It is a way of helping people understand their own health condition and involving them actively in its management.[153][154]
Surgery
Weight loss surgery in those who are obese is an effective measure to treat diabetes.[155] Many are able to maintain normal blood sugar levels with little or no medication following surgery[156] and long-term mortality is decreased.[157] There however is some short-term mortality risk of less than 1% from the surgery.[158] The body mass index cutoffs for when surgery is appropriate are not yet clear.[157] It is recommended that this option be considered in those who are unable to get both their weight and blood sugar under control.[159][160]
Some ethnic groups such as South Asians, Pacific Islanders, Latinos, and Native Americans are at particularly high risk of developing type 2 diabetes.[23] Type 2 diabetes in normal weight individuals represents 60 to 80 percent of all cases in some Asian countries. The mechanism causing diabetes in non-obese individuals is poorly understood.[163][164][165]
Rates of diabetes in 1985 were estimated at 30million, increasing to 135million in 1995 and 217million in 2005.[18] This increase is believed to be primarily due to the global population aging, a decrease in exercise, and increasing rates of obesity.[18] Traditionally considered a disease of adults, type2 diabetes is increasingly diagnosed in children in parallel with rising obesity rates.[10] The five countries with the greatest number of people with diabetes as of 2000 are India having 31.7million, China 20.8million, the United States 17.7million, Indonesia 8.4million, and Japan 6.8million.[166] It is recognized as a global epidemic by the World Health Organization.[1]
Diabetes is one of the first diseases described[21] with an Egyptian manuscript from c.1500BCE mentioning "too great emptying of the urine."[167][168] The first described cases are believed to be of type1 diabetes.[167] Indian physicians around the same time identified the disease and classified it as madhumeha or honey urine noting that the urine would attract ants.[167] The term "diabetes" or "to pass through" was first used in 230BCE by the Greek Apollonius Memphites.[167] The disease was rare during the time of the Roman empire with Galen commenting that he had only seen two cases during his career.[167]
Type1 and type2 diabetes were identified as separate conditions for the first time by the Indian physicians Sushruta and Charaka in 400–500AD with type1 associated with youth and type2 with being overweight.[167] Effective treatment was not developed until the early part of the 20th century when the Canadians Frederick Banting and Charles Best discovered insulin in 1921 and 1922.[167] This was followed by the development of the long acting NPH insulin in the 1940s.[167]
In 1916, Elliot Joslin proposed that in people with diabetes, periods of fasting are helpful.[169] Subsequent research has supported this, and weight loss is a first line treatment in type 2 diabetes.[169]
Research
Researchers developed the Diabetes Severity Score (DISSCO), a tool that might better than the standard blood test at identify if a person's condition is declining.[170][171] It uses a computer algorithm to analyse data from anonymised electronic patient records and produces a score based on 34 indicators.[172][173]
Related Research Articles
Metabolic syndrome is a clustering of at least three of the following five medical conditions: abdominal obesity, high blood pressure, high blood sugar, high serum triglycerides, and low serum high-density lipoprotein (HDL).
Insulin resistance (IR) is a pathological condition in which cells in insulin-sensitive tissues in the body fail to respond normally to the hormone insulin or downregulate insulin receptors in response to hyperinsulinemia.
Metformin, sold under the brand name Glucophage, among others, is the main first-line medication for the treatment of Type2 diabetes, particularly in people who are overweight. It is also used in the treatment of polycystic ovary syndrome, and is sometimes used as an off-label adjunct to lessen the risk of metabolic syndrome in people who take antipsychotics. It has also been shown to inhibit inflammation, and is not associated with weight gain. Metformin is taken orally.
Drugs used in diabetes treat diabetes mellitus by decreasing glucose levels in the blood. With the exception of insulin, most GLP-1 receptor agonists, and pramlintide, all diabetes medications are administered orally and are thus called oral hypoglycemic agents or oral antihyperglycemic agents. There are different classes of hypoglycemic drugs, and selection of the appropriate agent depends on the nature of diabetes, age, and situation of the person, as well as other patient factors.
Pioglitazone, sold under the brand name Actos among others, is an anti-diabetic medication used to treat type 2 diabetes. It may be used with metformin, a sulfonylurea, or insulin. Use is recommended together with exercise and diet. It is not recommended in type 1 diabetes. It is taken by mouth.
Gestational diabetes is a condition in which a person without diabetes develops high blood sugar levels during pregnancy. Gestational diabetes generally results in few symptoms; however, it increases the risk of pre-eclampsia, depression, and of needing a Caesarean section. Babies born to individuals with poorly treated gestational diabetes are at increased risk of macrosomia, of having hypoglycemia after birth, and of jaundice. If untreated, diabetes can also result in stillbirth. Long term, children are at higher risk of being overweight and of developing type 2 diabetes.
Sulfonylureas or sulphonylureas are a class of organic compounds used in medicine and agriculture. The functional group consists of a sulfonyl group (-S(=O)2) with its sulphur atom bonded to a nitrogen atom of a ureylene group (N,N-dehydrourea, a dehydrogenated derivative of urea). The side chains R1 and R2 distinguish various sulfonylureas. Sulfonylureas are the most widely used herbicide.
Large for gestational age (LGA) is a term used to describe infants that are born with an abnormally high weight, specifically in the 90th percentile or above, compared to other babies of the same developmental age. Macrosomia is a similar term that describes excessive birth weight, but refers to an absolute measurement, regardless of gestational age. Typically the threshold for diagnosing macrosomia is a body weight between 4,000 and 4,500 grams, or more, measured at birth, but there are difficulties reaching a universal agreement of this definition.
The term diabetes includes several different metabolic disorders that all, if left untreated, result in abnormally high concentrations of a sugar called glucose in the blood. Diabetes mellitus type 1 results when the pancreas no longer produces significant amounts of the hormone insulin, usually owing to the autoimmune destruction of the insulin-producing beta cells of the pancreas. Diabetes mellitus type 2, in contrast, is now thought to result from autoimmune attacks on the pancreas and/or insulin resistance. The pancreas of a person with type 2 diabetes may be producing normal or even abnormally large amounts of insulin. Other forms of diabetes mellitus, such as the various forms of maturity-onset diabetes of the young, may represent some combination of insufficient insulin production and insulin resistance. Some degree of insulin resistance may also be present in a person with type 1 diabetes.
Inhibitors of dipeptidyl peptidase 4 are a class of oral hypoglycemics that block the enzyme dipeptidyl peptidase-4 (DPP-4). They can be used to treat diabetes mellitus type 2.
A diabetic diet is a diet that is used by people with diabetes mellitus or high blood sugar to minimize symptoms and dangerous complications of long-term elevations in blood sugar.
Dapagliflozin, sold under the brand names Farxiga (US) and Forxiga (EU) among others, is a medication used to treat type 2 diabetes. It is also used to treat adults with heart failure and chronic kidney disease. It reversibly inhibits sodium-glucose co-transporter 2 (SGLT-2) in the renal proximal convoluted tubule to reduce glucose reabsorption and increase urinary glucose excretion.
Prediabetes is a component of metabolic syndrome and is characterized by elevated blood sugar levels that fall below the threshold to diagnose diabetes mellitus. It usually does not cause symptoms but people with prediabetes often have obesity, dyslipidemia with high triglycerides and/or low HDL cholesterol, and hypertension. It is also associated with increased risk for cardiovascular disease (CVD). Prediabetes is more accurately considered an early stage of diabetes as health complications associated with type 2 diabetes often occur before the diagnosis of diabetes.
Remogliflozin etabonate (INN/USAN) is a drug of the gliflozin class for the treatment of non-alcoholic steatohepatitis ("NASH") and type 2 diabetes. Remogliflozin was discovered by the Japanese company Kissei Pharmaceutical and is currently being developed by BHV Pharma, a wholly owned subsidiary of North Carolina, US-based Avolynt, and Glenmark Pharmaceuticals through a collaboration with BHV. In 2002, GlaxoSmithKline (GSK) received a license to use it. From 2002 to 2009, GSK carried out a significant clinical development program for the treatment of type-2 diabetes mellitus in various nations across the world and obesity in the UK. Remogliflozin etabonate's pharmacokinetics, pharmacodynamics, and clinical dose regimens were characterized in 18 Phase I and 2 Phase II investigations. Due to financial concerns, GSK stopped working on remogliflozin and sergliflozin, two further SGLT2 inhibitors that were licensed to the company, in 2009. Remogliflozin was commercially launched first in India by Glenmark in May 2019.
Glucagon-like peptide-1 (GLP-1) receptor agonists, also known as GLP-1 analogs, GLP-1DAs or incretin mimetics, are a class of anorectic drugs that reduce blood sugar and energy intake by activating the GLP-1 receptor. They mimic the actions of the endogenous incretin hormone GLP-1 that is released by the gut after eating.
Prevention of type 2 diabetes can be achieved with both lifestyle changes and use of medication. The American Diabetes Association categorizes people with prediabetes, who have glycemic levels higher than normal but do not meet criteria for diabetes, as a high-risk group. Without intervention, people with prediabetes progress to type 2 diabetes with a 5% to 10% rate. Diabetes prevention is achieved through weight loss and increased physical activity, which can reduce the risk of diabetes by 50% to 60%.
Empagliflozin, sold under the brand name Jardiance, among others, is an antidiabetic medication used to improve glucose control in people with type2 diabetes. It is taken by mouth.
Diabetes mellitus, often known simply as diabetes, is a group of common endocrine diseases characterized by sustained high blood sugar levels. Diabetes is due to either the pancreas not producing enough insulin, or the cells of the body becoming unresponsive to the hormone's effects. Classic symptoms include thirst, polyuria, weight loss, and blurred vision. If left untreated, the disease can lead to various health complications, including disorders of the cardiovascular system, eye, kidney, and nerves. Diabetes accounts for approximately 4.2 million deaths every year, with an estimated 1.5 million caused by either untreated or poorly treated diabetes.
Dulaglutide, sold under the brand name Trulicity among others, is a medication used for the treatment of type 2 diabetes in combination with diet and exercise. It is also approved in the United States for the reduction of major adverse cardiovascular events in adults with type 2 diabetes who have established cardiovascular disease or multiple cardiovascular risk factors. It is a once-weekly injection.
SGLT2 inhibitors are a class of medications that inhibit sodium-glucose transport proteins in the nephron, unlike SGLT1 inhibitors that perform a similar function in the intestinal mucosa. The foremost metabolic effect of this is to inhibit reabsorption of glucose in the kidney and therefore lower blood sugar. They act by inhibiting sodium/glucose cotransporter 2 (SGLT2). SGLT2 inhibitors are used in the treatment of type 2 diabetes. Apart from blood sugar control, gliflozins have been shown to provide significant cardiovascular benefit in people with type 2 diabetes. As of 2014, several medications of this class had been approved or were under development. In studies on canagliflozin, a member of this class, the medication was found to enhance blood sugar control as well as reduce body weight and systolic and diastolic blood pressure.
1 2 Fasanmade OA, Odeniyi IA, Ogbera AO (June 2008). "Diabetic ketoacidosis: diagnosis and management". African Journal of Medicine and Medical Sciences. 37 (2): 99–105. PMID18939392.
1 2 3 4 5 6 7 "Causes of Diabetes". National Institute of Diabetes and Digestive and Kidney Diseases. June 2014. Archived from the original on 2 February 2016. Retrieved 10 February 2016.
1 2 3 Maruthur NM, Tseng E, Hutfless S, Wilson LM, Suarez-Cuervo C, Berger Z, etal. (June 2016). "Diabetes Medications as Monotherapy or Metformin-Based Combination Therapy for Type 2 Diabetes: A Systematic Review and Meta-analysis". Annals of Internal Medicine. 164 (11): 740–51. doi:10.7326/M15-2650. PMID27088241. S2CID32016657.
↑ Moscou S (2013). "Getting the word out: advocacy, social marketing, and policy development and enforcement". In Truglio-Londrigan M, Lewenson SB (eds.). Public health nursing: practicing population-based care (2nded.). Burlington, MA: Jones & Bartlett Learning. p.317. ISBN978-1-4496-4660-8. OCLC758391750.
1 2 3 4 5 6 7 8 9 10 Ripsin CM, Kang H, Urban RJ (January 2009). "Management of blood glucose in type 2 diabetes mellitus". American Family Physician. 79 (1): 29–36. PMID19145963.
↑ Pasquier F (October 2010). "Diabetes and cognitive impairment: how to evaluate the cognitive status?". Diabetes & Metabolism. 36 (Suppl 3): S100-5. doi:10.1016/S1262-3636(10)70475-4. PMID21211730.
↑ Akinpelu OV, Mujica-Mota M, Daniel SJ (March 2014). "Is type 2 diabetes mellitus associated with alterations in hearing? A systematic review and meta-analysis". The Laryngoscope. 124 (3): 767–776. doi:10.1002/lary.24354. PMID23945844. S2CID25569962.
↑ Abdullah A, Peeters A, de Courten M, Stoelwinder J (September 2010). "The magnitude of association between overweight and obesity and the risk of diabetes: a meta-analysis of prospective cohort studies". Diabetes Research and Clinical Practice. 89 (3): 309–19. doi:10.1016/j.diabres.2010.04.012. PMID20493574.
↑ Saad F, Gooren L (March 2009). "The role of testosterone in the metabolic syndrome: a review". The Journal of Steroid Biochemistry and Molecular Biology. 114 (1–2): 40–43. doi:10.1016/j.jsbmb.2008.12.022. PMID19444934. S2CID22222112.
↑ Nieto-Martínez R, González-Rivas JP, Medina-Inojosa JR, Florez H (November 2017). "Are Eating Disorders Risk Factors for Type 2 Diabetes? A Systematic Review and Meta-analysis". Current Diabetes Reports (Systematic review and meta-analysis). 17 (12): 138. doi:10.1007/s11892-017-0949-1. PMID29168047. S2CID3688434.
↑ Cobelli C, Toffolo GM, Dalla Man C, Campioni M, Denti P, Caumo A, etal. (July 2007). "Assessment of beta-cell function in humans, simultaneously with insulin sensitivity and hepatic extraction, from intravenous and oral glucose tests". American Journal of Physiology. Endocrinology and Metabolism. 293 (1): E1–E15. doi:10.1152/ajpendo.00421.2006. PMID17341552.
↑ Salazar J, Chávez-Castillo M, Rojas J, Ortega A, Nava M, Pérez J, etal. (2020-07-23). "Is "Leptin Resistance" Another Key Resistance to Manage Type 2 Diabetes?". Current Diabetes Reviews. 16 (7): 733–749. doi:10.2174/1573399816666191230111838. PMID31886750. S2CID209510992.
↑ Yasumoto Y, Miyazaki H, Ogata M, Kagawa Y, Yamamoto Y, Islam A, etal. (December 2018). "Glial Fatty Acid-Binding Protein 7 (FABP7) Regulates Neuronal Leptin Sensitivity in the Hypothalamic Arcuate Nucleus". Molecular Neurobiology. 55 (12): 9016–9028. doi:10.1007/s12035-018-1033-9. PMID29623545. S2CID4632807.
↑ O'Gorman DJ, Krook A (September 2011). "Exercise and the treatment of diabetes and obesity". The Medical Clinics of North America. 95 (5): 953–969. doi:10.1016/j.mcna.2011.06.007. PMID21855702.
↑ Nield L, Summerbell CD, Hooper L, Whittaker V, Moore H (July 2008). Nield L (ed.). "Dietary advice for the prevention of type 2 diabetes mellitus in adults". The Cochrane Database of Systematic Reviews (3): CD005102. doi:10.1002/14651858.CD005102.pub2. hdl:10149/92337. PMID18646120. S2CID23039006. (Retracted)
↑ Mannucci E, Giaccari A, Gallo M, Bonifazi A, Belén ÁD, Masini ML, etal. (February 2022). "Self-management in patients with type 2 diabetes: Group-based versus individual education. A systematic review with meta-analysis of randomized trails". Nutrition, Metabolism, and Cardiovascular Diseases. 32 (2): 330–336. doi:10.1016/j.numecd.2021.10.005. PMID34893413. S2CID244580173.
↑ Davis N, Forbes B, Wylie-Rosett J (June 2009). "Nutritional strategies in type 2 diabetes mellitus". The Mount Sinai Journal of Medicine, New York. 76 (3): 257–268. doi:10.1002/msj.20118. PMID19421969.
↑ Muley A, Fernandez R, Ellwood L, Muley P, Shah M (May 2021). "Effect of tree nuts on glycemic outcomes in adults with type 2 diabetes mellitus: a systematic review". JBI Evidence Synthesis. 19 (5): 966–1002. doi:10.11124/JBISRIR-D-19-00397. PMID33141798. S2CID226250006.
↑ Chen X, Yang L, Zhai SD (December 2012). "Risk of cardiovascular disease and all-cause mortality among diabetic patients prescribed rosiglitazone or pioglitazone: a meta-analysis of retrospective cohort studies". Chinese Medical Journal. 125 (23): 4301–6. PMID23217404.
1 2 Schulman AP, del Genio F, Sinha N, Rubino F (September–October 2009). ""Metabolic" surgery for treatment of type 2 diabetes mellitus". Endocrine Practice. 15 (6): 624–31. doi:10.4158/EP09170.RAR. PMID19625245.
↑ International Diabetes Federation (2021). IDF Diabetes Atlas(PDF) (10ed.). International Diabetes Federation. p.33. ISBN978-2-930229-98-0. Retrieved 18 March 2022.
↑ Kahn CR, Ferris HA, O'Neill BT (2020). "Pathophysiology of Type 1 Diabetes Mellitus: Epidemiology". Williams Textbook of Endocrinology (14ed.). Elsevier. pp.1349–1370.
This page is based on this Wikipedia article Text is available under the CC BY-SA 4.0 license; additional terms may apply. Images, videos and audio are available under their respective licenses.